These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 33246972)

  • 1. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study.
    Pastor-Barriuso R; Pérez-Gómez B; Hernán MA; Pérez-Olmeda M; Yotti R; Oteo-Iglesias J; Sanmartín JL; León-Gómez I; Fernández-García A; Fernández-Navarro P; Cruz I; Martín M; Delgado-Sanz C; Fernández de Larrea N; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Larrauri A; Pollán M;
    BMJ; 2020 Nov; 371():m4509. PubMed ID: 33246972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
    Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Hernán MA; Pérez-Olmeda M; Sanmartín JL; Fernández-García A; Cruz I; Fernández de Larrea N; Molina M; Rodríguez-Cabrera F; Martín M; Merino-Amador P; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R;
    Lancet; 2020 Aug; 396(10250):535-544. PubMed ID: 32645347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey.
    Mutevedzi PC; Kawonga M; Kwatra G; Moultrie A; Baillie V; Mabena N; Mathibe MN; Rafuma MM; Maposa I; Abbott G; Hugo J; Ikalafeng B; Adelekan T; Lukhele M; Madhi SA
    Int J Epidemiol; 2022 May; 51(2):404-417. PubMed ID: 34718591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis.
    Yang W; Kandula S; Huynh M; Greene SK; Van Wye G; Li W; Chan HT; McGibbon E; Yeung A; Olson D; Fine A; Shaman J
    Lancet Infect Dis; 2021 Feb; 21(2):203-212. PubMed ID: 33091374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study.
    Laxminarayan R; B CM; G VT; Arjun Kumar KV; Wahl B; Lewnard JA
    Lancet Infect Dis; 2021 Dec; 21(12):1665-1676. PubMed ID: 34399090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).
    Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP;
    Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of COVID-19 on Mortality in Spain: Monitoring Excess Mortality (MoMo) and the Surveillance of Confirmed COVID-19 Deaths.
    León-Gómez I; Mazagatos C; Delgado-Sanz C; Frías L; Vega-Piris L; Rojas-Benedicto A; Larrauri A
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Implementation of a Nationwide Population-Based Longitudinal Survey of SARS-CoV-2 Infection in Spain: The ENE-COVID Study.
    Pastor-Barriuso R; Pérez-Gómez B; Oteo-Iglesias J; Hernán MA; Pérez-Olmeda M; Fernández-de-Larrea N; Molina M; Fernández-García A; Martín M; Cruz I; Sanmartín JL; León-Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R; Pollán M
    Am J Public Health; 2023 May; 113(5):525-532. PubMed ID: 36893375
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020.
    Murhekar MV; Bhatnagar T; Selvaraju S; Rade K; Saravanakumar V; Vivian Thangaraj JW; Kumar MS; Shah N; Sabarinathan R; Turuk A; Anand PK; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chakraborty D; Rangaraju C; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Salim Khan SM; Haq I; Kumar MS; Laxmaiah A; Madhuka ; Mahapatra A; Mitra A; Nirmala AR; Pagdhune A; Qurieshi MA; Ramarao T; Sahay S; Sharma YK; Shrinivasa MB; Shukla VK; Singh PK; Viramgami A; Wilson VC; Yadav R; Girish Kumar CP; Luke HE; Ranganathan UD; Babu S; Sekar K; Yadav PD; Sapkal GN; Das A; Das P; Dutta S; Hemalatha R; Kumar A; Narain K; Narasimhaiah S; Panda S; Pati S; Patil S; Sarkar K; Singh S; Kant R; Tripathy S; Toteja GS; Babu GR; Kant S; Muliyil JP; Pandey RM; Sarkar S; Singh SK; Zodpey S; Gangakhedkar RR; S Reddy DC; Bhargava B
    Indian J Med Res; 2020 Jul & Aug; 152(1 & 2):48-60. PubMed ID: 32952144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 seroprevalence in the city of Puerto Madryn: Underdiagnosis and relevance of children in the pandemic.
    Schonfeld D; Fernández H; Ramírez J; Acosta D; Becerra J; Wettstein M; Strella T; Vaccaro M; Arias S; Rodríguez Calvo V; Neme R; Pérez-Chada D
    PLoS One; 2022; 17(3):e0263679. PubMed ID: 35286328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
    Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
    Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Case-fatality rates of SARS-CoV-2 infection according to Autonomous Communities during the second epidemic wave in Spain].
    Ruiz-García A; Vitelli-Storelli F; Serrano-Cumplido A; Segura-Fragoso A; Calderón-Montero A; Mico-Pérez RM; Barquilla-García A; Morán-Bayón Á; Linares M; Olmo-Quintana V; Martín-Sánchez V;
    Semergen; 2022; 48(4):252-262. PubMed ID: 35437189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys.
    Angulo FJ; Finelli L; Swerdlow DL
    JAMA Netw Open; 2021 Jan; 4(1):e2033706. PubMed ID: 33399860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
    Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
    Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ENE-COVID nationwide serosurvey served to characterize asymptomatic infections and to develop a symptom-based risk score to predict COVID-19.
    Pérez-Gómez B; Pastor-Barriuso R; Pérez-Olmeda M; Hernán MA; Oteo-Iglesias J; Fernández de Larrea N; Fernández-García A; Martín M; Fernández-Navarro P; Cruz I; Sanmartín JL; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R; Pollán M;
    J Clin Epidemiol; 2021 Nov; 139():240-254. PubMed ID: 34126206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
    Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
    JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High SARS-CoV-2 Exposure in Rural Southern Mozambique After Four Waves of COVID-19: Community-Based Seroepidemiological Surveys.
    de Jesus Á; Ernesto R; Massinga AJ; Nhacolo F; Munguambe K; Timana A; Nhacolo A; Messa A; Massora S; Escola V; Enosse S; Gunjamo R; Funzamo C; Mwenda JM; Okeibunor J; Garcia-Basteiro A; Guinovart C; Mayor A; Mandomando I
    Influenza Other Respir Viruses; 2024 Jun; 18(6):e13332. PubMed ID: 38838093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020.
    Gidding HF; Machalek DA; Hendry AJ; Quinn HE; Vette K; Beard FH; Shilling HS; Hirani R; Gosbell IB; Irving DO; Hueston L; Downes M; Carlin JB; O'Sullivan MV; Dwyer DE; Kaldor JM; Macartney K
    Med J Aust; 2021 Mar; 214(4):179-185. PubMed ID: 33538019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020.
    Bogogiannidou Z; Vontas A; Dadouli K; Kyritsi MA; Soteriades S; Nikoulis DJ; Mouchtouri VΑ; Koureas M; Kazakos EI; Spanos EG; Gioula G; Ntzani EE; Eleftheriou AA; Vatopoulos A; Petinaki E; Papaevangelou V; Speletas M; Tsiodras S; Hadjichristodoulou C
    Euro Surveill; 2020 Aug; 25(31):. PubMed ID: 32762796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.